The contribution of NUCB1 and ANXA5 in tumor progression and drug responses in DLBCL remains controversial, so revealing their exact roles in DLBCL behavior and prognosis needs further investigation. The gene discussed is NUCB1; the disease is diffuse large B-cell lymphoma.